LCL

LCL Biopharmaceutical is a clinical-stage biotechnology company based in Suzhou, China, dedicated to the development of innovative cell therapies for hematological malignancies and solid tumors. The company leverages its proprietary CAR-T and TCR-T technology platforms to design next-generation therapies, including multi-targeting and universal CAR-T (UCAR-T) products. Its lead program, LCL-M001, is a dual-targeting CAR-T therapy directed against CD19 and CD22, currently in clinical trials for B-cell lymphomas and leukemias. Additionally, LCL is advancing a pipeline of candidates targeting solid tumor antigens such as Glypican-3 and Mesothelin. Supported by leading venture capital firms, LCL Biopharmaceutical aims to provide transformative treatment options for patients with refractory or relapsed cancers.